[Novo Nordisk responds to "Simeglutide reflux drugs": supports and fully cooperates in cracking down on illegal activities, and continues to promote the authorization and certification channel system] On September 22, regarding the issue of semaglutide "reflux drugs", Novo Nordisk China told reporters that in response to recent reports, the company always puts patient safety first, and has always firmly supported and fully cooperated with relevant national departments to crack down on illegal activities such as medical insurance reflux drugs in accordance with the law to safeguard the safety of the national medical insurance fund and the legitimate rights and interests of patients. In the statement, Novo Nordisk stated that it will continue to work with industry chain partners such as medical institutions, retail pharmacies, and e-commerce platforms to jointly support standardized medication management and patient education, continue to promote the authorization and certification channel system (including brand direct supply and official authorization channels), and collaboratively improve the quality management and traceability capabilities of the entire drug circulation chain to provide patients with drugs and professional services with clear sources, compliant storage and transportation, and traceability. (The Paper)